We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity to Report Q1 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Revvity is set to report Q1 2026 results with revenues expected to rise 6.1% year over year.
Diagnostics remains the main growth driver, led by immunodiagnostics and reproductive health strength.
Life Sciences shows early stabilization, with pharma demand improving, but academic markets are still weak.
Revvity, Inc. (RVTY - Free Report) is slated to report first-quarter 2026 results on May 05, before market open.
In the last reported quarter, the company delivered an earnings surprise of 4.29%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.13%.
Revvity appears to have exited 2025 with improving momentum, supported by resilient Diagnostics performance and early signs of stabilization in Life Sciences. While Life Sciences demand likely remained subdued amid continued weakness in academic and government spending, a gradual recovery in pharma and biotech activity may have provided some support. Diagnostics, however, is expected to have remained the primary growth driver, aided by strength in reproductive health and immunodiagnostics, partially offset by persistent China-related headwinds, positioning the company for a cautiously improving near-term outlook.
So far this year, RVTY’s shares have declined 10.5% compared to the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period.
Image Source: Zacks Investment Research
Q1 Estimates
The Zacks Consensus Estimate for first-quarter revenues is pegged at $705.2 million, indicating a gain of 6.1% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $1.02 per share, indicating an improvement of 1% year over year.
Factors Driving Q1 Performance
Revvity is set to report its upcoming quarterly results against a backdrop of gradually stabilizing end markets, though near-term performance is likely to have reflected a mix of improving demand signals and lingering macro and policy-related headwinds. The company exited the prior quarter with 4% organic growth and better-than-expected earnings, supported by strength in Diagnostics and early signs of recovery in Life Sciences. However, management maintained a cautious stance, pointing to continued uncertainty in pharma funding, academic demand, and China-related pressures.
At the consolidated level, revenue growth is expected to remain modest, likely in the low-single-digit range, as improving biopharma sentiment and early-stage funding recovery begin to offset prior weakness. The academic and government spending — impacted previously by funding volatility and the U.S. government shutdown — may have continued to weigh on demand. Margins could have faced near-term pressure from tariffs, FX fluctuations and ongoing reinvestments, though cost-efficiency initiatives should provide some offset as they ramp through the year.
Segment-wise, Diagnostics is likely to have remained the primary growth driver. The segment previously delivered 7% organic growth, led by strength in immunodiagnostics and reproductive health. Newborn screening demand and solid execution outside China are expected to have supported continued momentum, though China remains a drag due to volume-based procurement and pricing pressures. Our estimate for the Life Sciences segment’s revenues is pegged at $365.4 million, up 7.4% year over year.
In Life Sciences, trends are stabilizing but not yet robust. Pharma and biotech demand is likely to have shown low-single-digit growth, aided by improving funding conditions and M&A activity, while academic and government end markets remained weak. Instrument demand, after multiple quarters of decline, has begun to stabilize, and consumables are likely to have performed better than expected, suggesting early-cycle recovery. However, management’s conservative outlook implies limited near-term acceleration. Our estimate for the Diagnostic segment’s revenues is pegged at $343.8 million, up 6% year over year.
Additionally, software and AI initiatives — particularly the Signals platform and the launch of Xynthetica — could have begun contributing incrementally, though material revenue impact is likely longer term. Overall, while Revvity appears positioned for gradual recovery, the upcoming quarter will likely reflect a transition phase with modest growth and mixed segment performance.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Revvity this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for RVTY. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Here are some other medical product stocks worth considering, as these also have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Revvity to Report Q1 Earnings: What's in Store for the Stock?
Key Takeaways
Revvity, Inc. (RVTY - Free Report) is slated to report first-quarter 2026 results on May 05, before market open.
In the last reported quarter, the company delivered an earnings surprise of 4.29%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.13%.
Revvity appears to have exited 2025 with improving momentum, supported by resilient Diagnostics performance and early signs of stabilization in Life Sciences. While Life Sciences demand likely remained subdued amid continued weakness in academic and government spending, a gradual recovery in pharma and biotech activity may have provided some support. Diagnostics, however, is expected to have remained the primary growth driver, aided by strength in reproductive health and immunodiagnostics, partially offset by persistent China-related headwinds, positioning the company for a cautiously improving near-term outlook.
So far this year, RVTY’s shares have declined 10.5% compared to the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period.
Image Source: Zacks Investment Research
Q1 Estimates
The Zacks Consensus Estimate for first-quarter revenues is pegged at $705.2 million, indicating a gain of 6.1% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $1.02 per share, indicating an improvement of 1% year over year.
Factors Driving Q1 Performance
Revvity is set to report its upcoming quarterly results against a backdrop of gradually stabilizing end markets, though near-term performance is likely to have reflected a mix of improving demand signals and lingering macro and policy-related headwinds. The company exited the prior quarter with 4% organic growth and better-than-expected earnings, supported by strength in Diagnostics and early signs of recovery in Life Sciences. However, management maintained a cautious stance, pointing to continued uncertainty in pharma funding, academic demand, and China-related pressures.
At the consolidated level, revenue growth is expected to remain modest, likely in the low-single-digit range, as improving biopharma sentiment and early-stage funding recovery begin to offset prior weakness. The academic and government spending — impacted previously by funding volatility and the U.S. government shutdown — may have continued to weigh on demand. Margins could have faced near-term pressure from tariffs, FX fluctuations and ongoing reinvestments, though cost-efficiency initiatives should provide some offset as they ramp through the year.
Segment-wise, Diagnostics is likely to have remained the primary growth driver. The segment previously delivered 7% organic growth, led by strength in immunodiagnostics and reproductive health. Newborn screening demand and solid execution outside China are expected to have supported continued momentum, though China remains a drag due to volume-based procurement and pricing pressures. Our estimate for the Life Sciences segment’s revenues is pegged at $365.4 million, up 7.4% year over year.
In Life Sciences, trends are stabilizing but not yet robust. Pharma and biotech demand is likely to have shown low-single-digit growth, aided by improving funding conditions and M&A activity, while academic and government end markets remained weak. Instrument demand, after multiple quarters of decline, has begun to stabilize, and consumables are likely to have performed better than expected, suggesting early-cycle recovery. However, management’s conservative outlook implies limited near-term acceleration. Our estimate for the Diagnostic segment’s revenues is pegged at $343.8 million, up 6% year over year.
Additionally, software and AI initiatives — particularly the Signals platform and the launch of Xynthetica — could have begun contributing incrementally, though material revenue impact is likely longer term. Overall, while Revvity appears positioned for gradual recovery, the upcoming quarter will likely reflect a transition phase with modest growth and mixed segment performance.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Revvity this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for RVTY. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Revvity Inc. Price and EPS Surprise
Revvity Inc. price-eps-surprise | Revvity Inc. Quote
Other Stocks Worth a Look
Here are some other medical product stocks worth considering, as these also have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.